About this trial
The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.
Eligibility criteria
Qualifiers
Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);
Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;
EGFR gene testing positive, EGFR 19del/L858R mutation;
Receiving postoperative EGFR-TKI targeted adjuvant therapy;
Disqualifiers
Patients negative for EGFR;
Incomplete surgical resection (R1, R2);
Did not receive EGFR-TKI targeted therapy after surgery;
Recurrent or advanced stage patients;
Trial design
Treatments tested in this trial
- Comprehensive analysis through laboratory tests, imaging techniques, and clinical data